MarkSKaminskiMD

Oncology • Ann Arbor, MI

Professor, Internal Medicine Director, Lymphoma Clinic

Join to view full profile

Dr. Kaminski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Kaminski's full profile

Already have an account?

Office
1500 East Medical Center Dr
Rm 4316, Univ of Michigan Cancer Center
Ann Arbor, MI 48109
Phone+1 734-936-5310

Fax+1 734-647-9654
Is this information wrong?

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1978 - 1981
Stanford University School of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1981 - Present
MI State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2008-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma Start of enrollment: 2005 Aug 01
Active, not recruiting
Phase 2
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy Start of enrollment: 2007 Apr 01
Completed
Phase 1
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2009 Sep 01
Completed
Phase 1, Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Tycel J Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa, Philip Boonstra, Tera Lynn Mayer, Victoria Nachar, Ryan A Wilcox, Shannon A Carty, Yasmin...> ;Blood Advances. 2023 Aug 22
The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
John S Runge, Anna B Brown, Tycel J Phillips, Mark S Kaminski, Shannon A Carty, Ryan A Wilcox> ;Journal of Oncology Pharmacy Practice. 2023 Apr 1
79 citations
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Andrew D. Zelenetz, Leo I. Gordon, Julie E. Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, L. Elizabeth Budde, Paolo Caimi, Sven de V...> ;Journal of the National Comprehensive Cancer Network. 2021 Nov 1
14 citations
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Nan Hu, Fangyang Wang, Tianyu Sun, Jing Zhang, Denzil Bernard, Shilin Xu, Shaomeng Wang, Mark S. Kaminski, Sumana Devata, Tycel Phillips, Sami N. Malek, Zhengfan Xu> ;Clinical Cancer Research. 2021 Apr 15
3 citations
Clinical application of next generation sequencing in lymphoma
Anthony J Scott, Molly Tokaz, Maryann Shango, Sumana Devata, Shannon A. Carty, Mark S. Kaminski, Arul M. Chinnaiyan, Tycel Phillips, Ryan A. Wilcox> ;Leukemia & Lymphoma. 2021 Mar 21
85 citations
Hodgkin lymphoma, version 2.2020
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Kirsten M Boughan, Bout...> ;Journal of the National Comprehensive Cancer Network. 2020 Jun 1
3 citations
Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas
Taylor M Weis, Bernard L. Marini, Victoria R Nachar, Anna Brown, Tycel Phillips, Julia Brown, Ryan A. Wilcox, Mark S. Kaminski, Sumana Devata, Anthony J. Perissinotti> ;Leukemia & Lymphoma. 2020 Apr 15
4 citations
Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.
Jennifer Girard, John C. Reneau, Sumana Devata, Ryan A. Wilcox, Mark S. Kaminski, Jessica Mercer, Shannon A. Carty, Tycel Phillips> ;Oncotargets and Therapy. 2019 Sep 30
178 citations
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.
Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula L. Bockenstedt, Erica L. Campagnaro, Sumana Devata, Scott D. Gitlin, Mark S. Kaminski, Alice M. Cusick, Tycel Phill...> ;The Lancet. Haematology. 2019 Sep 16
16 citations
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.
Marcus Geer, Emily Roberts, Maryann Shango, Brian G. Till, Stephen D. Smith, Hashim Abbas, Brian T. Hill, Jason B. Kaplan, Paul M. Barr, Paolo Caimi, Deborah M. Stephe...> ;British Journal of Haematology. 2019 Jul 1
105 citations
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Paolo Caimi, Julie E. Chang, Julio C. Chavez, Beth Christian, Luis Fayad, ...> ;Journal of the National Comprehensive Cancer Network. 2019 Jun 1
6 citations
Structural variation of centromeric endogenous retroviruses in human populations and their impact on cutaneous T-cell lymphoma, Sézary syndrome, and HIV infection.
Mark H. Kaplan, Mark S. Kaminski, Judith Estes, Scott D. Gitlin, Joseph Zahn, James T. Elder, Trilokraj Tejasvi, Elizabeth Gensterblum, Amr H. Sawalha, Joseph P. McGow...> ;BMC Medical Genomics. 2019 May 2
19 citations
Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and MTOR
Fangyang Wang, Damián Gatica, Zhang Xiao Ying, Luke F. Peterson, Peter K. Kim, Denzil Bernard, Kamlai Saiya-Cork, Shaomeng Wang, Mark S. Kaminski, Alfred E. Chang, Tyc...> ;The Journal of Clinical Investigation. 2019 Apr 1
15 citations
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study.
Jeff P. Sharman, Andres Forero-Torres, Luciano J. Costa, Ian W. Flinn, Lowell Inhorn, Kevin Kelly, Alberto Bessudo, Luis Fayad, Mark S. Kaminski, Andrew M. Evens, Chri...> ;Leukemia & Lymphoma. 2019 Mar 21
2 citations
Do Deauville Scores Improve the Clinical Utility of End-of-Therapy FDG PET Scans for Pediatric Hodgkin Lymphoma?
Laura K Sedig, Jason J Bailey, Ka Kit Wong, Richard K.J. Brown, Mark S. Kaminski, Raymond J. Hutchinson> ;AJR. American Journal of Roentgenology. 2019 Feb 1
50 citations
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Ter...
Mazyar Shadman, Hongli Li, Lisa M. Rimsza, John P. Leonard, Mark S. Kaminski, Rita M. Braziel, Catherine M. Spier, Ajay K. Gopal, David G. Maloney, Bruce D. Cheson, Sh...> ;Journal of Clinical Oncology. 2018 Jan 22
163 citations
NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, Philip J. Bierman, Robert T...> ;Journal of the National Comprehensive Cancer Network. 2018 Mar 1
18 citations
Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).
Janie Y. Zhang, Sumana Devata, Mark S. Kaminski, Tycel Phillips, Tera Mayer, Nathanael G. Bailey, Ryan A. Wilcox, Briski, R., Robert Briski> ;American Journal of Hematology. 2018 Mar 1
17 citations
A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.
Philip S. Boonstra, Avery Polk, Noah A. Brown, Alexandra C. Hristov, Nathanael G. Bailey, Mark S. Kaminski, Tycel Phillips, Sumana Devata, Tera Mayer, Ryan A. Wilcox> ;American Journal of Hematology. 2017 Dec 1
1 citations
Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.
Peter L. Roberson, Lauren B. Smith, Meredith A. Morgan, Matthew J. Schipper, Scott J. Wilderman, Anca M. Avram, Mark S. Kaminski, Yuni K. Dewaraja> ;Cancer Biotherapy & Radiopharmaceuticals. 2017 Nov 1
97 citations
Hodgkin lymphoma version 1.2017
Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, Karl Bernat, Philip J. Bierman, Kristie A. B...> ;Journal of the National Comprehensive Cancer Network. 2017 May 1
189 citations
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Ahmed I. Younes, Patrick Hilden, Bertrand Coiffier, Anton Hagenbeek, Gilles Salles, Walter R. Wilson, John F. Seymour, Kara M. Kelly, John G. Gribben, M Pfreunschuh, F...> ;Annals of Oncology. 2017 Jul 1
3 citations
Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiati...
Carol M. Moinpour, Joseph M. Unger, Patricia A. Ganz, Alice B. Kornblith, Ellen R. Gaynor, Mindy A Bowers, Gretchen S. Gatti, Mark S. Kaminski, Harry P. Erba, Ting Wan...> ;Journal of Cancer Survivorship. 2017 Feb 1
35 citations
A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome.
Walter Hanel, Charles W. Ross, Thomas F. Anderson, Mark S. Kaminski, Alexandra C. Hristov, Ryan A. Wilcox, Briski, R., Robert Briski> ;American Journal of Hematology. 2016 Dec 1
26 citations
Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.
Zhang Xiao Ying, Meiyan Jin, Luke F. Peterson, Denzil Bernard, Kamlai Saiya-Cork, Mehmet Yildiz, Shaomeng Wang, Mark S. Kaminski, Alfred E. Chang, Daniel J. Klionsky, ...> ;Clinical Cancer Research. 2016 Nov 1
Join now to see all

Abstracts/Posters

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of...
Mark S Kaminski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Grant Support

Iodine 131 Anti-B1 Antibody For Non-Hodgkin'S LymphomaNational Center For Research Resources2000–2002
Retreatment Of NON Hodgkins Lymphoma W/ Iodine 131 Anti B1 AntibodyNational Center For Research Resources1999–2002
I 131 Anti B1 Antibody In NON Hodgkins Lymphoma VS Unlabeled Anti B1National Center For Research Resources1999–2002
(131) Iodine-B1 Radioimmunotherapy Of Advanced Nonhodgkin'S LymphomaNational Center For Research Resources1998–2002
Radioimmunotherapy Of LymphomaNational Cancer Institute1992–2000
Radiolabeled Monoclonal PAN B Cell Antibody In The Treatment Of B Cell LymphomasNational Center For Research Resources1996–1999
(131) Iodine-B1 Radioimmunotherapy Of Advanced NON Hodgkin'S LymphomaNational Center For Research Resources1997
Coulter Clone 131I B1 Radioimmunotherapy Of NON Hodgkins LymphomaNational Center For Research Resources1996
Anti-Tumor Effects Of Anti-Idiotype AntibodiesNational Cancer Institute1990–1992
NCI Clinical Invstigator Award ProgramNational Cancer Institute1986–1988
Anti-Tumor Effects Of Anti-Idiotype AntibodiesNational Cancer Institute1985